• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A coxib a day won't keep the doctor away.

作者信息

Topol Eric J, Falk Gary W

机构信息

Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

出版信息

Lancet. 2004;364(9435):639-40. doi: 10.1016/S0140-6736(04)16906-7.

DOI:10.1016/S0140-6736(04)16906-7
PMID:15325809
Abstract
摘要

相似文献

1
A coxib a day won't keep the doctor away.一天一片昔布类药物并不能让你远离医生。
Lancet. 2004;364(9435):639-40. doi: 10.1016/S0140-6736(04)16906-7.
2
[Lumiracoxib reduces ulcer complications in comparison to NSAR].与非甾体类抗炎药相比，氯美昔布可降低溃疡并发症的发生率。
Z Orthop Ihre Grenzgeb. 2005 Mar-Apr;143(2):158-9. doi: 10.1055/s-2005-868456.
3
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.在治疗性关节炎研究和胃肠道事件试验（TARGET）中罗美昔布与萘普生和布洛芬的比较：心血管结局的随机对照试验
Lancet. 2004;364(9435):675-84. doi: 10.1016/S0140-6736(04)16894-3.
4
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.在治疗性关节炎研究与胃肠道事件试验（TARGET）中，罗美昔布与萘普生和布洛芬的比较：溃疡并发症的减少：随机对照试验。
Lancet. 2004;364(9435):665-74. doi: 10.1016/S0140-6736(04)16893-1.
5
Evidence in practice--number 3: Cox 2 inhibitors.实践证据——第3条：环氧化酶-2抑制剂
Br J Gen Pract. 2004 Nov;54(508):880-1.
6
Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.罗美昔布治疗关节炎研究及胃肠道事件试验——研究设计与患者人口统计学特征
Aliment Pharmacol Ther. 2004 Jul 1;20(1):51-63. doi: 10.1111/j.1365-2036.2004.02026.x.
7
The COX 2 selective inhibitors: what the newspapers have not told you.COX-2 选择性抑制剂：报纸未告诉你的事。
Bull NYU Hosp Jt Dis. 2007;65(3):229-41.
8
Safety and efficacy of lumiracoxib compared with NSAIDs.氯美昔布与非甾体抗炎药相比的安全性和有效性。
Nat Clin Pract Gastroenterol Hepatol. 2005 Jan;2(1):14-5. doi: 10.1038/ncpgasthep0067.
9
COX-2 inhibitors. Magic bullets or merely mortal?环氧化酶-2抑制剂。神奇子弹还是普通药物？
Harv Health Lett. 2000 Feb;25(4):4.
10
[Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].[选择性环氧化酶-2抑制剂。耐受性优于非甾体抗炎药加抗酸剂]
MMW Fortschr Med. 2004 Apr 8;146(15):66.

引用本文的文献

1
Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing.选择性COX-2抑制剂：从成功到争议以及重新利用的探索之路。
Pharmaceuticals (Basel). 2022 Jul 3;15(7):827. doi: 10.3390/ph15070827.
2
Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis.鲁米昔布：其对骨关节炎治疗临床影响的证据
Core Evid. 2007 Nov 30;2(2):131-50.
3
Clinical use and pharmacological properties of selective COX-2 inhibitors.选择性环氧化酶-2抑制剂的临床应用及药理特性
Eur J Clin Pharmacol. 2008 Mar;64(3):233-52. doi: 10.1007/s00228-007-0400-7. Epub 2007 Nov 13.
4
Inadequate use of preventive strategies in patients receiving NSAIDs.在使用 NSAIDs 的患者中，预防策略的使用不足。
Clin Drug Investig. 2005;25(4):265-70. doi: 10.2165/00044011-200525040-00006.
5
Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials.非甾体抗炎药与心肌梗死：观察性研究和随机对照试验证据的比较系统评价
Ann Rheum Dis. 2007 Oct;66(10):1296-304. doi: 10.1136/ard.2006.068650. Epub 2007 Mar 7.
6
The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.万络的故事——无痛却多害：制药行业行为引发的伦理担忧
J Anesth. 2006;20(4):348-51. doi: 10.1007/s00540-006-0432-7.
7
Cyclooxygenase-2 (PTGS2) inhibitors augment the rate of hexose transport in L6 myotubes in an insulin- and AMPKalpha-independent manner.环氧化酶-2（PTGS2）抑制剂以不依赖胰岛素和AMPKα的方式提高L6肌管中的己糖转运速率。
Diabetologia. 2006 Mar;49(3):562-70. doi: 10.1007/s00125-005-0122-2. Epub 2006 Jan 31.
8
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.COX-2抑制对心血管影响的生物学基础：治疗挑战与机遇
J Clin Invest. 2006 Jan;116(1):4-15. doi: 10.1172/JCI27291.
9
[Trends of non-steroidal anti-inflammatory drugs use in Spain, 1990 through 2003].[1990年至2003年西班牙非甾体抗炎药的使用趋势]
Aten Primaria. 2005 Nov;36(8):424-33. doi: 10.1157/13081056.
10
Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.服用环氧化酶-2抑制剂或传统非甾体抗炎药患者的心肌梗死风险：基于人群的巢式病例对照分析
BMJ. 2005 Jun 11;330(7504):1366. doi: 10.1136/bmj.330.7504.1366.